RxDoctor Payments Data

Michael Darin, MD

Sleep Medicine · New Orleans, LANPI 1285855973

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.4% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Jazz Pharmaceuticals Inc. accounts for 65.4% of it on its own, with 7 other manufacturers making up the rest. That places this record below the midpoint for sleep medicine clinicians in LA, where the typical reported total is $2,943.

$1,163in general payments, 2019–2025

Across 31 payments — averaging $37.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$761
  • Inspire Medical Systems, Inc.$145
  • Harmony Biosciences LLC$116
  • Axsome Therapeutics, Inc.$51
  • Avadel CNS Pharmaceuticals, LLC$51
  • Fisher & Paykel Healthcare Inc$21
  • plus $19 from 2 others

What the payments were for

  • Food & beverage$1,06491%
  • Education$1009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,163 in reported general payments places this provider in the 35th percentile of 20 sleep medicine providers in Louisiana.

See all sleep medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,007
Medicare patients
326
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant30$13,995
SunosiSolriamfetol Hcl12$11,483
Modafinil34$8,200
Azelastine Hcl21$804
Armodafinil14$706
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$466
Fluticasone Propionate14$244
Trazodone Hcl18$222
Clonazepam30$197
Gabapentin33$183
Zolpidem Tartrate46$168
Venlafaxine Hcl ErVenlafaxine Hcl14$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$51$11,48312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 20 sleep medicine providers in Louisiana.

Other sleep medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →